You are here

  • Home
  • Archive
  • Volume 91, Issue 3
  • Introducing opt-out HIV testing in an acute medical admissions unit: does it improve testing uptake in those with lobar pneumonia?

Article Text

Article menu
Download PDFPDF
Letter
Introducing opt-out HIV testing in an acute medical admissions unit: does it improve testing uptake in those with lobar pneumonia?

https://doi.org/10.1136/sextrans-2014-051723

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Funding We have received funding from Gilead Sciences to support the implementation of MAU testing. We have received funding from Bristol-Myers Squibb and Viiv towards other HIV testing initiatives.

    • Competing interests CO has received educational and research grants as well as lecture fees and advisory board fees from BMS, Abbvie, Gilead, Jannsen, Viiv, GSK and Boehringer Ingelheim. JT and JS have received educational grants and or lectureship fees from Gilead, Jannsen and BMS. JS and JT have received educational support from Viiv.

    • Provenance and peer review Not commissioned; externally peer reviewed.